Tag: Pharma News

  • SA HIV Treatment Programme Faces Historic Slowdown

    South Africa’s massive HIV response has hit a significant roadblock. The country’s leading mathematical tool for tracking HIV trends, the Thembisa model, has released its latest estimates. They reveal that the South African HIV treatment programme recorded its slowest annual growth in two decades. Between 2024 and 2025, the number of people receiving antiretroviral treatment (ART) increased by just 40,000.…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Chinese Pharmaceutical Innovation Impacts Healthcare Landscape

    The traditional pharmaceutical order, once anchored in Western centres, has fundamentally shifted. We now inhabit a bipolar industry landscape dominated by the United States and China. This transformation carries significant implications for patients, investors, and policymakers worldwide. Chinese Pharmaceutical Innovation Drives Global Research Boom China has rapidly closed the gap in medical research. In several key areas, it has now…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Lilly Hits $1 Trillion Valuation with Weight-Loss Success

    In a historic milestone for the pharmaceutical industry, Eli Lilly surged to a market value of $1 trillion on Friday. It became the first drugmaker to join an exclusive club previously dominated by technology heavyweights. This event marked the moment Lilly hit a $1 trillion valuation. It highlighted the company’s rapid ascent as a global powerhouse in the weight-loss sector.…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Lenacapavir in Short Supply Amid HIV Epidemic in Africa

    International health activists and civil society organisations have launched a scathing critique of pharmaceutical giant Gilead Sciences and the US government. They say that Lenacapavir is in short supply and woefully inadequate to slow Africa’s epidemic. The backlash follows a joint announcement earlier this week by the US government and the Global Fund to Fight HIV/Aids, Tuberculosis and Malaria regarding…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in

  • Trade Tariffs and Their Impact on Pharmaceuticals

    The pharmaceutical industry is bracing for a significant financial blow. Analysts forecast costs of between $13 billion and $19 billion following a new transatlantic trade deal. This deal will subject branded medicines to a hefty 15% tariff. Officials confirmed the landmark trade agreement between the European Union and the United States on Sunday. It marks the end of the historic…

    Continue reading with a Health Matters subscription

    Subscribers read every article in full, receive the daily briefing and have access to the complete archive.

    SubscribeLog in